GENOR BIOPHARMA DL-00002 (F:67N0) — Stock Price

€0.18 EUR
▲ 0.00% today

GENOR BIOPHARMA DL-00002 (F:67N0) is currently trading at €0.18 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €0.15 and €0.47. This page tracks GENOR BIOPHARMA DL-00002's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see how efficiently does GENOR BIOPHARMA DL-00002 generate cash.

GENOR BIOPHARMA DL-00002 (67N0) Stock Price Chart — Daily History & Trading Volume

The chart below tracks GENOR BIOPHARMA DL-00002's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.

GENOR BIOPHARMA DL-00002 Income Statement — Revenue, Profit & Earnings by Year

GENOR BIOPHARMA DL-00002's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 2024202320222021
Total Revenue €206.23 Million €0.00 €15.93 Million €0.00
Cost of Revenue €1.34 Million €0.00 €983.00K €0.00
Gross Profit €204.89 Million €0.00 €14.95 Million €0.00
Research & Development €202.78 Million €564.28 Million €583.88 Million €612.72 Million
SG&A €71.71 Million €125.24 Million €217.27 Million €305.95 Million
Total Operating Expenses €238.98 Million €685.82 Million €802.14 Million €918.67 Million
Operating Income €-32.75 Million €-685.82 Million €-786.21 Million €-918.67 Million
EBITDA — — — —
EBIT — — — —
Interest Expense €112.00K €888.00K €2.86 Million €2.36 Million
Income Before Tax €-35.13 Million €-677.50 Million €-732.42 Million €-866.31 Million
Income Tax Expense — — — —
Net Income €-51.28 Million €-674.36 Million €-730.21 Million €-865.22 Million

GENOR BIOPHARMA DL-00002 Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes GENOR BIOPHARMA DL-00002's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 2024202320222021
Total Assets €1.29 Billion €1.45 Billion €2.12 Billion €2.86 Billion
Total Current Assets €1.07 Billion €1.24 Billion €1.72 Billion €2.39 Billion
Cash & Equivalents — — — —
Short-term Investments — — — —
Net Receivables — — — —
Inventory €0.00 €5.67 Million €47.40 Million €49.65 Million
Property, Plant & Equipment — — — —
Goodwill €17.82 Million €17.82 Million €21.75 Million €21.75 Million
Total Liabilities €138.05 Million €256.18 Million €309.87 Million €369.73 Million
Total Current Liabilities €122.09 Million €229.53 Million €260.39 Million €313.19 Million
Long-term Debt — — — —
Net Debt — — — —
Total Stockholder Equity €1.15 Billion €1.19 Billion €1.80 Billion €2.49 Billion
Retained Earnings €-6.84 Billion €-6.79 Billion €-6.12 Billion €-5.39 Billion

GENOR BIOPHARMA DL-00002 Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how GENOR BIOPHARMA DL-00002 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 2024202320222021
Operating Cash Flow €-121.98 Million €-425.12 Million €-577.61 Million €-623.74 Million
Capital Expenditures €1.57 Million €1.03 Million €12.96 Million €71.39 Million
Free Cash Flow €-123.55 Million €-426.15 Million €-590.56 Million €-695.13 Million
Investing Cash Flow — — — —
Financing Cash Flow — — — —
Dividends Paid — — — —
Stock-Based Compensation €11.64 Million €60.91 Million €48.24 Million €123.69 Million
Depreciation €18.22 Million €76.89 Million €53.68 Million €60.74 Million
Change in Cash €-115.53 Million €-425.95 Million €-647.94 Million €-660.43 Million

GENOR BIOPHARMA DL-00002 Earnings History — EPS Actual vs. Analyst Estimates

Track GENOR BIOPHARMA DL-00002's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Mar 26, 2026 — — —
Aug 26, 2025 — — —
Mar 25, 2025 — — —